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Highly immunocompromised pediatric and adult hematopoietic cell transplant (HCT)
recipients frequently experience respiratory infections caused by viruses that are less
virulent in immunocompetent individuals. Most of these infections, with the exception of
rhinovirus as well as adenovirus and parainfluenza virus in tropical areas, are seasonal
variable and occur before and after HCT. Infectious disease management includes
sampling of respiratory specimens from nasopharyngeal washes or swabs as well as
sputum and tracheal or tracheobronchial lavages. These are subjected to improved
diagnostic tools including multiplex PCR assays that are routinely used allowing for
expedient detection of all respiratory viruses. Disease progression along with high
mortality is frequently associated with respiratory syncytial virus, parainfluenza virus,
influenza virus, and metapneumovirus infections. In this review, we discuss clinical
findings and the appropriate use of diagnostic measures. Additionally, we also discuss
treatment options and suggest new drug formulations that might prove useful in treating
respiratory viral infections. Finally, we shed light on the role of the state of immune
reconstitution and on the use of immunosuppressive drugs on the outcome of infection.
Keywords: hematopoietic cell transplantation, respiratory virus infection, co-infection, immunosuppression,
antiviral therapy, investigational drugs, infection outcome
RESPIRATORY VIRUS INFECTIONS IN PEDIATRIC AND ADULT
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
RECIPIENTS
In early prospective studies evaluating the incidence of respiratory viral infections in allogeneic
HCT recipients conducted by two members of the European Group for Blood and Marrow
Transplantation (EBMT), frequencies of these infections were determined at 4 and 7.1%,
respectively. Furthermore, the highest mortality rates from fatal pneumonia were found with RSV
of 60% and AdV of 75% (Ljungman, 1997). Today, 20 years on, these continue to be frequent
Abbreviations: AdV, adenovirus; BAL, bronchoalveolar lavage; CMV, cytomegalovirus; GvHD, graft-versus-host
disease; HBoV, human bocavirus; HCoV, human coronavirus; HCT, hematopoietic cell transplantation; HMPV,
human metapneumovirus; IFV, influenza virus; ISI, immunodeficiency scoring index; IVIG, intravenous polyvalent
immunoglobulins; LRI, lower respiratory tract infection; PCR, polymerase chain reaction; PIV, parainfluenza virus; RhV,
rhinovirus; RSI, radiology severity index; RSV, respiratory syncytial virus; URI, upper respiratory tract infection.
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infections and still contribute to significant mortality with rates
ranging between 10 and 50% if infection progresses to the lower
respiratory tract (Boeckh, 2008; Englund et al., 2011; Renaud
and Campbell, 2011; Protheroe et al., 2012; Chemaly et al., 2014;
Spahr et al., 2018).
Human pathogenic viruses frequently causing respiratory
infections in the allogeneic HCT setting include RSV, AdV, IFV,
PIV, HMPV, RhV, HCoV, and HBoV (Renaud and Englund, 2012;
Abbas et al., 2017). Such respiratory virus infections contribute
to morbidity and mortality for a number of reasons. Firstly, HCT
recipients suffer from prolonged immunosuppression and a lack
of both humoral and T cell-mediated immunity impairs viral
clearance (Kohlmeier and Woodland, 2009; Schmidt and Varga,
2018). In addition, these patients are usually antibody-depleted
and the strength of the conditioning regimen and the ongoing
immunosuppressive therapy diminishes the antiviral immune
response further. Moreover, the type of graft may have an impact
on the immune response and pediatric HCT recipients may
also be immunologically naïve because of their age. Secondly,
viral factors shape the outcome. Respiratory viruses vary in their
pathogenicity, i.e., they cause more severe disease compared
with other viruses. Also, there is the capacity for certain strains
of a given respiratory virus to display increased virulence as
is the case with IFV and it is therefore important to identify
viral and host genes that determine virulence. Thirdly, a limited
number of effective antivirals or the emergence of drug resistance
also hamper successful treatment. Finally, factors like persisting
infections, co-infections and co-morbidities will also influence
the outcome.
In contrast to immunocompetent individuals, HCT recipients
present with prolonged viral shedding and have a higher rate
of progression from URI to LRI (Chemaly et al., 2014; de Lima
et al., 2014; Kim et al., 2014). Increased viral loads and protracted
infections raise the likelihood of progression that differs between
viruses. URI has been commonly defined as laboratory-confirmed
viral nasal wash or swab with pharyngitis, cough, otitis, nasal
discharge and/or congestion in the absence of infiltrates on chest
x-ray or computed tomography (CT) scan and hypoxemia, and
LRI has been defined as laboratory-confirmed viral nasal wash
or swab in the presence of infiltrates on chest x-ray or CT scan
suggestive of a viral respiratory infection but not necessarily
detection of viral nucleic acid in samples obtained from BAL
(Shah et al., 2014). In HCT recipients, RSV is most frequently
detected, followed by HMPV and PIV. In 5–50% of cases, these
viruses progress to LRI, often complicate the transplant course
by causing airflow obstruction or bronchiolitis obliterans and
also increase the rate of mortality up to 50% (Chemaly et al.,
2014). Several respiratory viruses share a number of risk factors
associated with LRI occurrence. It is worth noting that CMV also
represents an opportunistic pathogen that is causally related to
pneumonia and LRI. However, CMV will not be discussed in this
review since it is not primarily considered a respiratory virus.
That said, CMV is a pathogen that frequently occurs as part of
a simultaneous infection – indeed a respiratory viral infection
can often precede bacterial and fungal infections – thus further
complications associated with respiratory virus infections need
to be acknowledged.
In this review, we will focus on respiratory virus infections
and, particularly, those that are commonly detected after HCT.
We highlight risk factors that facilitate progression from URI
to LRI and discuss diagnostic approaches. Current treatment
strategies along with new treatment options will be discussed.
Adenovirus
Adenovirus is a member of the adenoviridae that circulates
throughout the year. Currently, 90 human types are known
which are further divided into seven species A–G1 (accessed
on 20 August 2018). Alongside conjunctivitis and diarrhea,
AdV can cause pharyngitis, bronchitis and pneumonia but also
lethal hepatitis or severe bloody colitis. Pertinent to this review,
AdV is a pathogen associated with severe complications in
immunosuppressed pediatric HCT recipients including increased
mortality (Leen et al., 2006; Feuchtinger et al., 2007; Lion, 2014;
Feucht et al., 2015; Hiwarkar et al., 2018). In adult patients,
AdV infections are less commonly reported. However, it is
possible this perception might be biased by reduced frequency of
screening in adults. A study in adult allogeneic HCT recipients
reported an infection rate of 2.5%. Pneumonia occurred in 24%
of cases and was the most common cause of death associated
with AdV (Yilmaz et al., 2013). An important consideration
is that AdV infections infrequently present with respiratory
symptoms at the onset of infection; instead they are commonly
detected by monitoring stool (Lo et al., 2013; Lion, 2014). Indeed,
gastrointestinal shedding pre-transplant has been demonstrated
to reflect increased risk of viremia after HCT (Kosulin et al.,
2018a).
Human Bocavirus
Human bocavirus was identified in 2005 as a human pathogen
that causes respiratory tract infections in infants. It has been
assigned to the parvoviridae and received its name because
of sequence homology to two other members in the genus
Bocaparvovirus, Bovine parvovirus infecting cattle and Canine
minute virus infecting dogs (Allander et al., 2005). Currently,
four HBoV variants have been described. Like HBoV3, HBoV1
can enter an episomal state, allowing the establishment of a
persistent infection (Kapoor et al., 2011). Whereas HBoV2,
HBoV3, and HBoV4 cause gastroenteritis and are genetically
diverse, HBoV1 exhibits a stronger association with LRI than
enteritis, often in conjunction with other respiratory pathogens,
and has limited genetic diversity although reinfections with
different variants occur (Arden et al., 2006; Ditt et al., 2008;
Arthur et al., 2009; Kapoor et al., 2010; Wang et al., 2010;
Martin et al., 2015). Symptoms following infection include cough,
dyspnea, pharyngitis, bronchitis, pneumonia, and diarrhea.
Several reports have suggested that HBoV1 can cause severe
infections on its own and is not a mere bystander virus
(Schildgen et al., 2008; Ursic et al., 2011; Edner et al.,
2012). Likewise, HBoV can cause life-threatening infections
and prolonged shedding in immunocompromised patients, and
for immunocompetent children a median shedding time of
50 days has been reported (Kupfer et al., 2006; Allander, 2008;
1http://hadvwg.gmu.edu/
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Koskenvuo et al., 2008; de Vries et al., 2009; Martin et al.,
2015). This long shedding period might lead to more severe
disease in immunocompromised children (Schenk et al., 2007).
Importantly, HBoV does not exhibit seasonality and thus remains
a threat throughout the year.
Human Coronavirus
Human coronavirus belongs to the coronaviridae that are
endemic in humans. Annually HCoV are responsible for 15–
30% of URI with pharyngitis and rhinitis in immunocompetent
hosts. Historically, two common HCoV were known: HCoV-
229E and HCoV-OC43. However, the emergence of Severe Acute
Respiratory Syndrome-Coronavirus (SARS-CoV) along with two
further HCoV (HCoV-HKU1 and HCoV-NL63) has expanded
the family (van der Hoek et al., 2004; Woo et al., 2005). In
contrast to the low incidence of bronchitis or pneumonia in
healthy children, severe clinical features have been described
in immunocompromised patients. Both the presence of a
respiratory co-pathogen (RSV) and host factors like young
age < 5 years and an immunocompromised status were reported
to contribute to LRI. However, it should be noted that only 10
children with HCT were included (Ogimi et al., 2017b, 2018a).
In separate studies, HCoV have been associated with increased
mortality and prolonged shedding in the HCT setting (Milano
et al., 2010; Renaud and Campbell, 2011). Risk factors for
prolonged shedding (at least 21 days) in the upper respiratory
tract were determined in a cohort of 44 patients and included
high viral load, myeloablative conditioning, and prior high-dose
steroid use (Ogimi et al., 2017a). Of 44 patients, 31 samples
were analyzed shown to contain evidence of HCoV-OC43 (35%),
HCoV-NL63 (32%), HCoV-HKU1 (19%), and HCoV-229E (13%)
infection. Analysis for duration of shedding showed that none
of the strains appeared to cause longer shedding compared with
others. In addition, genomic approaches investigated whether
viral genome evolution could identify genetic changes associated
with prolonged shedding. Identification of such changes could
aid the development of new antiviral agents. Single nucleotide
polymorphisms could not be identified until day thirty after the
onset of viral shedding. This finding might not be surprising
given the protracted evolution rate of HCoV. However, overt
viral genome changes might occur at a later time point, and
changes in genome composition might result in a modification
of the treatment strategy (Ogimi et al., 2017a). In another study,
HCoV were examined in BAL (Ogimi et al., 2017b). The median
time to HCoV LRI occurrence was 302 days after HCT. Among
23 BAL samples analyzed, 48% were HCoV-OC43, HCoV-NL63
was detected in 22%, HCoV-229E in 17% and HCoV-HKU1
in 13%. Although somewhat limited because of sample size,
these data show a similar frequency and order of detected viral
strains compared to those detected from nasal samples with
the exception of HCoV-HKU1 which was predominant in nasal
samples (Ogimi et al., 2017a). The detection of RSVs did not
change clinical outcome.
Influenza Virus
Influenza virus, an orthomyxoviridae member, exhibits high
genomic variability due to an absence of proofreading activity
in its RNA – a process that contributes to antigenic drift. As
some IFV strains are more virulent than others, the strain of IFV
impacts on severity, depending on circulating strains, and this
can be impacted upon by the composition of the vaccine and
also the uptake of vaccine in the population. Individuals with
a compromised immune system such as the elderly and HCT
recipients are at increased risk of complications and death, and
outbreaks in HCT units have been reported (Lalayanni et al.,
2010; Suyani et al., 2011). In HCT recipients, fever maybe absent
in about 19% of cases as might classical symptoms such as sore
throat, nasal congestion and discharge, cough, chills and myalgia
(Ljungman et al., 2011). As with other respiratory viruses, IFV
shedding in HCT patients has been reported to be prolonged
with a median of 12 days; lymphopenia correlated with the
duration of shedding, and steroid use > 1 mg/kg increased IFV
secretion (Khanna et al., 2009; Boudreault et al., 2011; Engelhard
et al., 2013). Infants may present with sepsis-like symptoms
and pneumonia. Complications in adults include pneumonia,
myocarditis, encephalitis and Guillain-Barré syndrome. As with
PIV infections (see below), bacterial and fungal co-infections
with IFV are known (Nichols et al., 2004b; Engelhard et al.,
2013). Disease progression to LRI takes place in up to 35%
and mortality ranges between 15 and 28% in patients diagnosed
with pneumonia. Therefore, early treatment within 2 days of
presenting with symptoms has been favored (Whimbey et al.,
1994; Nichols et al., 2004b; Chemaly et al., 2006; Kmeid et al.,
2016). While risk factors have been validated for RSV and PIV,
equivalent quality indicators are limited for IFV. Potential risk
factors that might result in LRI are lymphopenia and neutropenia
as well as increased age (>65 years) while steroid use is unclear
(Ljungman et al., 2001; Chemaly et al., 2006; Choi et al., 2012).
IFV genome detection in blood was associated with hypoxemia,
respiratory failure, and overall mortality (Choi et al., 2012).
Kmeid et al. (2016) applied an ISI that had been developed for
RSV to identify patients with IFV infection who might run at
risk to develop progression to LRI (Shah et al., 2014). According
to variables such as age, neutrophil and lymphocyte counts,
conditioning regimen, steroid use and time from transplantation,
HCT recipients were grouped into low, moderate, and high
risk immunodeficiency categories. A high risk score was applied
if the score was between 7 and 12 and was likely to include
ANC < 500/mm3 (score 3) and/or ALC < 200/mm3 (3),
age ≥ 40 years (2), myeloablative regimen (1), GvHD (1), steroid
use within the last 30 days (1) and recent (within the last 30 days)
or pre-engraftment allogeneic HCT (1). Patients with a high risk
score had a significantly higher probability of developing LRI
compared to the low risk group (Kmeid et al., 2016).
Human Metapneumovirus
Human metapneumovirus, formerly a member of the
paramyxoviridae now belonging to the pneumoviridae, was
identified in 2001 as an agent capable of causing respiratory
disease in children (van den Hoogen et al., 2001). In
immunocompetent individuals, HMPV causes symptomatic
URI and LRI predominantly in children or adults above 65 years
of age (Boivin et al., 2002). No specific symptoms that distinguish
HMPV from other viral respiratory infections exist. It has
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been reported that disease is more severe in case of a RSV
co-infection but these data are considered controversial. In
immunocompetent children, one study revealed that HMPV
with RSV co-infection increased bronchiolitis (Semple et al.,
2005), however, this could not be substantiated in other studies
that investigated single infections and co-infections for HMPV
and RSV (Moe et al., 2017; Yan et al., 2017). For both HMPV and
RSV, A and B types occur that can be distinguished by different
primer sets in PCR (Renaud et al., 2013). Immunocompromised
children are at higher risk of developing LRI with higher risk
of requiring intensive care treatment with increased mortality
(Chu et al., 2014). In a study of 21 HCT recipients, HPMV
infection was documented in the majority of patients but did not
cause any symptoms or disease (Debiaggi et al., 2006). However,
in a study that included 251 episodes of URI and LRI, 16 of the
22 episodes in which HPMV was detected occurred in HCT
recipients, resulting in an infection rate of approximately 6% of
all HCT patients (Williams et al., 2005). Another study revealed
HPMV in BAL samples from 5 of 163 patients who became
symptomatic within a month after engraftment, and fatality
reached up to 80% if BAL was positive for HMPV (Englund
et al., 2006). Progression to LRI has been reported to take place
between 21 and 40% (Renaud and Campbell, 2011). For HMPV,
risk factors for mortality include length between HCT and
infection; neutropenia, lymphopenia, low monocyte count at
diagnosis, and a steroid dose before diagnosis of ≥1 mg/kg (Seo
et al., 2016). In the latter study, the presence of co-pathogens
contributed to higher risk. Glucocorticoid application and
lymphopenia have been identified as risk factors that contribute
to progression from URI to LRI (Seo et al., 2016). In a systematic
review, HMPV progressed to LRI in 34% of cases and the
mortality rate increased from 6 to 27% when LRI was present but
no HMPV-associated risk factors for increased mortality could
be identified (Shah et al., 2016b).
Parainfluenza Virus
Parainfluenza virus is a member of the paramyxoviridae that
circulates throughout the year. PIV causes LRI in approximately
20% of healthy children (Bicer et al., 2013) and is also responsible
for life-threatening LRI in HCT recipients (Srinivasan et al.,
2011; Shah et al., 2016a). Four PIV serotypes are known. PIV
serotype 3 (PIV-3) is the most frequent occurring serotype and
has been responsible for infections after HCT (Cortez et al.,
2001; Nichols et al., 2004a; Maziarz et al., 2010; Hodson et al.,
2011). In one study comprising 3577 patients with PIV infection,
6.4% had an infection with PIV-3, and 24% of these patients
developed pneumonia (Nichols et al., 2001a). Another study
reported PIV infections in up to 18% of cases during the first
3 months post HCT (Peck et al., 2007). In 20–40% of patients
who experience URI, infection progresses to LRI with a median
time of 78 days. Virus-associated mortality is around 10% after
PIV infection but increases to 27% if infection progresses to LRI
(Nichols et al., 2001a; Srinivasan et al., 2011; Chemaly et al.,
2012; Ustun et al., 2012; Seo et al., 2014a; Shah et al., 2016a).
PIV risk factors for progression to LRI are lymphopenia, steroid
use and co-infections with other respiratory agents, however,
myeloablation and infections in the early post-transplant period
were variables with unclear association (Seo et al., 2014b;
Shah et al., 2016a). Pulmonary co-pathogens, e.g., Aspergillus
fumigatus, are often present in patients with pneumonia and
highly contribute to mortality (Nichols et al., 2001a; Ustun et al.,
2012).
Respiratory Syncytial Virus
Respiratory syncytial virus, now also belonging to the
pneumoviridae, is a frequent pathogen in infants and children
that causes URI with rhinitis and laryngitis but also bronchitis
and pneumonia if progression to LRI occurs. In HCT recipients,
RSV infections occur up to 30% (Martino et al., 2005; Khanna
et al., 2008; Avetisyan et al., 2009; Shah and Chemaly, 2011;
Waghmare et al., 2013). In approximately half of the HCT
recipients with URI caused by RSV, infection will progress and
result in pneumonia that is associated with average mortality
rates around 30% without effective treatment (Nichols et al.,
2001b; Boeckh et al., 2007; Khanna et al., 2008; Shah and
Chemaly, 2011; Seo et al., 2013; Waghmare et al., 2013).
Risk factors for progression to LRI include advanced age,
lymphopenia, myeloablative regimen, steroid use, GvHD and
pre-engraftment infection and occur at a mean of 38% (Nichols
et al., 2001b; Martino et al., 2005; Khanna et al., 2008; Shah
and Chemaly, 2011; Hirsch et al., 2013). Further, smoking
history, conditioning with high-dose total body irradiation
with 1200–1575 cGy and specifically an absolute lymphocyte
count ≤ 100/mm3 at URI onset were significantly associated
with progression to LRI. In contrast, lung function, steroid use,
lymphocyte engraftment dynamics, RSV subtypes and subtype-
specific neutralizing antibody levels were not associated with
progression, revealing transplant-related rather than viral factors
which might put a focus on the characterization of RSV-specific
T cells (Kim et al., 2014). In addition, absolute lymphocyte
counts of > 1000/mm3 at URI onset were protective and no
advance to LRI was observed. Another study that examined risk
factors for RSV RNA detection in serum or plasma identified
mechanical ventilation, neutropenia, monocytopenia as well as
thrombocytopenia as associated factors, however, lymphopenia
and steroid use did not increase the risk of RSV RNA plasma
detection (Waghmare et al., 2013). For that study, a median time
of 52 days to LRI onset was described.
As described for IFV, an ISI had been originally proposed
to stratify RSV-infected patients into groups based on their risk
of progression from URI to LRI and to evaluate RSV-related
mortality (Shah et al., 2014). This stratification should help
to identify patients who might profit from antiviral therapy
such as aerosolized ribavirin. This index is based on age,
absolute neutrophil and lymphocyte counts, acute or chronic
GvHD, myeloablative conditioning, corticosteroid use and time
of infection. However, validation of this index needs to be
performed in multicenter studies.
Rhinovirus
Rhinovirus, a member of the picornaviridae, comprises more
than 100 serotypes and are divided into the three species A,
B and C. There is no seasonal preference for RhV, however,
more infections might occur during spring and autumn. RhV are
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the most frequently detected community-associated respiratory
viruses that cause cough, a runny nose but also bronchitis
or pneumonia in HCT recipients (Ison et al., 2003; Milano
et al., 2010). Symptomatic RhV infections occur in 10–30% of
HCT recipients and initial high viral loads are associated with
prolonged shedding (Parody et al., 2007; Milano et al., 2010;
Ogimi et al., 2018b). A recent study showed that median shedding
time among patients with RhV infection was 9.5 days, and
18/38 (47%) of HCT recipients had prolonged RhV shedding (at
least 21 days; range, 2–89 days) that was similar for all three
species but the majority of patients (69%) shed RhV species
A. Risk factors for prolonged RhV shedding pointed to a high
initial viral load as defined by a Ct value below the median
(30.3) (Ogimi et al., 2018b). Infection control measures should
consider these long infection periods. Progression to LRI is
increasingly being detected and fatal outcomes due to RhV
infections have been described (Gutman et al., 2007; Jacobs et al.,
2013; Ogimi et al., 2018b).
FROM COLONIZATION TO
SYMPTOMATIC INFECTION AFTER HCT
Patients who reveal respiratory tract infection symptoms before
HCT should be tested for respiratory pathogens by multiplex
PCR. Campbell et al. analyzed data from 458 adult and
pediatric patients and identified 25% of patients to be positive
for at least one respiratory virus pre-transplant. Symptomatic
patients had lower survival 100 days after HCT compared
with patients with negative test results and increased overall
mortality. Since this risk was increased even if only RhV was
detected, the authors proposed to consider deferral of HCT
in symptomatic patients with any respiratory virus positive,
not just only in case of RSV, IFV, PIV, or HMPV detection.
Asymptomatic patients with a virus detected did not exhibit
higher mortality and HCT might proceed as planned; however,
it is unclear if these patients actually shed replicating virus
or if only viral nucleic acid is being detected. There was no
higher incidence of bronchoscopy in the symptomatic versus
the asymptomatic group. Any decision to delay transplant
has to consider HCT factors such as underlying disease, the
conditioning regimen associated with it and donor logistics
(Campbell et al., 2015). In a follow-up study that focused on
pediatric HCT recipients, Kim et al. (2017) detected respiratory
viruses pre-transplant in 81 of 218 patients. RhV were detected
in 24% of cases, followed by a group of viruses consisting of
AdV, RSV, HMPV PFV, and PIV (11%). Pre-transplant detection
was associated with increased hospitalization during the first
100 days, and HCoV was only detected pre-transplant in 2% of
cases.
Since the conditioning regimen might have an impact on
the incidence of respiratory virus infections pre-transplant,
patients with myeloablative and non-myeloablative conditioning
were compared. The incidences for respiratory virus infections
were similar among both groups. However, in contrast to
patients receiving non-myeloablative conditioning, LRI
are significantly increased during the first 100 days post
HCT when myeloablative regimen was given (Schiffer et al.,
2009).
Immediately after HCT in the neutropenic phase, patients
frequently develop febrile episodes and are especially prone
to bacterial infections. Therefore, they are often treated with
antibiotics to protect them from life-threatening bacterial
infections. This treatment alters microbiota composition
and has an impact on immune responses (Ichinohe et al.,
2011; Abt et al., 2012; Dyer et al., 2016). An immunodulatory
compound associated with microbiota is butyrate, a short chain
fatty acid that is important in maintaining gut microbiome
equilibrium as well as in controlling immune responses in organs
such as the lung (Donohoe et al., 2011; Chang et al., 2014).
In a recent study, Haak et al. (2018) investigated the influence
of butyrate on microbiota composition and its influence on
respiratory viral infections and the associated risk to develop LRI
in HCT recipients. Patients who received antibiotic treatment
resulting in altered microbiota colonization and diminished
butyrate-producing bacteria had a higher risk of developing
LRI indicating that the presence of butyrate-producing bacteria
appears to be protective (Haak et al., 2018). A recent analysis
from the Seattle group has shown that antibiotic exposure
before the onset of viral respiratory infection increases the risk
of progression from URI to LRI in case of HMPV, PIV and
RSV infection (Ogimi et al., 2018a). However, a certain class of
antibiotics that poses a particular risk could not be identified.
Another recent study described significant lower overall
survival for patients with respiratory virus infection accompanied
by bacterial co-infection that contributed to increased mortality
(Pinana et al., 2018). Risk factors for developing bacterial
co-infection following a respiratory viral infection were
steroid use ≥ 1mg/kg/d and CMV DNAemia requiring
antiviral therapy. Mortality-associated risk factors such as
lymphopenia < 0.5 × 109/ml, CMV DNAemia requiring
antiviral therapy at the time of viral LRI diagnosis and oxygen
support at the time of BAL were used to establish a risk score
in order to stratify patients to help predict mortality, no matter
if a co-infection was present or not. This new risk score was
compared to other scores including the ISI described above,
however, the application of ISI criteria did not prove useful to
predict mortality in this cohort. Currently, ISI does not include
co-infections as a variable, and future studies are needed to
validate and compare different risk scores (Pinana et al., 2018).
The profound lymphopenia after HCT has been described as a
risk factor in the study above and multiple other studies, and it
has recently been suggested that CD8 T cells may protect against
a secondary infection (Schmidt and Varga, 2018).
DIAGNOSTIC WORKUP
The fourth European Conference on Infections in Leukemia
(ECIL-4) developed guidelines for diagnosis and treatment on
several respiratory viruses (Hirsch et al., 2013). HCT candidates
and recipients with URI or LRI should be tested for respiratory
viruses to guide infection management and possible deferral of
transplantation. Specimens should be taken from the site of
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infection; for URI, pooled swabs should be analyzed and for LRI, a
tracheal aspirate or ideally a BAL should be performed. However,
patient circumstances often do not permit invasive procedures.
These guidelines favored a first-line screening for IFV A and
B, RSV, and PIV, however, with more advanced multiplex PCR
assays becoming available, all agents might be examined at once
(Waghmare et al., 2016).
Over the past years, more respiratory infections in HCT
recipients have been reported due to the development and use
of new diagnostic methods. Routine molecular diagnostics of
respiratory viruses nowadays includes multiplex PCR approaches
that have improved detection of respiratory agents in HCT
recipients (Leber et al., 2018; Sam et al., 2018). Multiplex
assays covering the relevant respiratory viral agents are preferred
over laborious and time-consuming viral culture and direct
fluorescence antibody assays because of its sensitivity, specificity
and rapid turnaround time. In addition, viral nucleic acid
quantification is important because determination of a viral
load might indicate prolonged viral shedding in case of RhV
(Ogimi et al., 2018b). However, this does not provide information
about active replication and viral culture techniques are not well
established, e.g., for HCoV.
A problem with virus detection is a lack of standardization
among assays since different primers, probes and techniques
are used (Huang et al., 2017). Nasal respiratory swabs are
routinely performed pre-transplant and should be collected in
case of suspected respiratory infection. A large prospective study
associated respiratory virus detection before transplantation with
prolonged hospitalization and decreased survival at day 100
(Campbell et al., 2015). RhV detection after a routine pre-
transplant screening can result in fatal infection, even if the
patient is asymptomatic and presents with regular findings on
chest CT (Milano et al., 2010; Campbell et al., 2015; Waghmare
et al., 2016). If any respiratory virus is identified by multiplex
PCR pre-transplant, HCT should be postponed (Bredius et al.,
2004; Peck et al., 2004; Hirsch et al., 2013). However, as occurs in
leukemia relapse cases, the time window from remission to HCT
can be narrow, thus making a decision difficult. Irrespective of
URI or LRI, transplant should be delayed if possible, probably
even in cases where data are scarce as is the case in HCoV and
HBoV infections. While episodes of both URI and LRI have
shown a higher mortality risk in symptomatic adults in contrast
to asymptomatic patients (Abandeh et al., 2013), transplant delay
should be recommended in symptomatic adults. However, in
pediatric patients who tend to shed virus more frequently than
adults and acquire viruses more frequently, transplant delay
should be considered on a case by case basis in asymptomatic
patients.
In aiding to determine progression from URI to LRI,
radiologic signs are considered an important component
although inter-observer variability is high and radiologic signs are
sometimes difficult to interpret (Elemraid et al., 2014; Franquet,
2018). It is important to perform useful radiologic diagnostics
in symptomatic patients with suspected LRI. Chest x-rays are
generally not recommended because lack of sensitivity but CT
should be performed to evaluate LRI. In children, chest x-rays
do not provide specific information in case of HMPV infection
where common findings include hyperinflation, atelectasis and
perihilar opacities (Hilmes et al., 2017).
In an attempt to try and provide a standardized framework
a scoring tool named the RSI has been established to quantify
severity of radiologic findings and correlate them with outcome
in PIV LRI. Infiltrate expansion, when longitudinally assessed by
RSI, was predictive of mortality in patients with PIV-associated
disease and discrepant results were obtained when CT and chest
X-ray findings were compared. Early signs suggest that the RSI
appears to be a useful tool to predict mortality but needs to be
validated in future studies (Sheshadri et al., 2018).
Computed tomography findings associated with LRI include
bronchial wall thickening and diffuse or patch-like ground glass
opacities as a sign of interstitial infiltrates (Franquet et al.,
2006; Herbst et al., 2013). However, radiologic approaches often
do not show clear signs of infection in symptomatic patients.
Additionally, the occurrence of simultaneous infections means
correlating a specific virus with CT findings is difficult. To
address this, a retrospective study by Kim et al. (2016) examined
CT scans from LRI patients with BAL specimens and single
infections of either RSV, IFV or PIV in order to identify virus-
characteristic CT lesions. Patch consolidations of at least one
centimeter or more than one segmental level were only observed
in PIV infections. Ground-glass opacities were identified in all
CT scans when IFV was detected and were less frequently seen
with PIV (detected in 71% of cases) and RSV (67%). Bronchial
wall thickening was prominent with IFV and RSV in about
two thirds of CT scans analyzed whereas it was seen in only
one third in PIV infections. Anatomically, RSV infection was
localized in the upper and middle lobes (44%), PIV preferentially
in the lower lobes (69%) and IFV infection resulted in a diffuse
pattern (Kim et al., 2016). However, due to the retrospective
nature of the study by Kim et al., no distinction between early
and late infection stage CT findings could be made which might
have revealed different patterns. Other studies similarly identified
ground-glass opacities for IFV infections (Franquet et al., 2006;
Kanne et al., 2007) and bronchial wall thickening combined with
nodules and tree-in-bud in RSV infections (Mayer et al., 2014).
Another small study also detected bronchial wall thickening
in patients with confirmed RSV infections but also ground-
glass opacities, and these findings were equally seen in hMPV
infections where lesions appeared to be more asymmetrical (Syha
et al., 2012). Although CT findings appear to be non-specific,
they might help to differentiate between pathogens causing
LRI if a thorough diagnostic workup including multiplex PCR





Infection control measures are of high importance and
should be in place in case of suspected or confirmed
respiratory virus infection (Boeckh, 2008). Since these viruses
are transmitted by close contact with infected individuals or
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contaminated material, hand hygiene is of utmost importance
since nosocomial infections have occurred that must be avoided
(Hoellein et al., 2016). The use of universal surgical mask might
also be useful to prevent respiratory viral infections after HCT
(Sung et al., 2016). Patients with documented respiratory virus
infection should be isolated with restricted contact and strict
protection measures should be applied (gloves, gowning, masks,
eye protection) to visitors and healthcare workers (Hirsch et al.,
2013). Since HCT recipients might shed these viruses for a long
time because of their impaired immunity, precautions should be
taken if a patient is discharged. For example, a patient should
be escorted through the outpatient clinic to avoid direct contact
with and spread to other patients, and prolonged isolation might
be necessary (Tomblyn et al., 2009; Hirsch et al., 2013). This
might be especially important for RhV in case high viral loads
are detected since shedding time in these patients exceeds 21 days
(Ogimi et al., 2018b). However, PIV-3 and HMPV infections
might go unrecognized in immunocompetent persons, thus
making it difficult to prevent infection (Nichols et al., 2001b;
Debiaggi et al., 2007; Shah et al., 2016b; Birger et al., 2018).
Reduction of Immunosuppression
Each time a respiratory tract infection is proven after HCT,
a reduction of immunosuppressive treatment should be the
response. A steroid dose greater than 1 or 2 mg/kg/day has been
proven to be an independent risk factor for overall mortality in
LRI with RhV (Seo et al., 2017), RSV (Shah et al., 2016a), HMPV,
and PIV (Waghmare et al., 2016). However, no correlation
between progression or mortality and steroid dose was found for
IFV (Waghmare et al., 2016).
Specific Drugs
Adenovirus
Adenovirus pneumonia is usually observed in AdV disseminated
disease. Preemptive treatment is recommended as soon as
viremia is higher or equal to 1000 copies/ml coupled with
lymphocyte counts below 300/mm3 and CD4 T lymphocyte
counts below 25/mm3 (Hiwarkar et al., 2017). This is particularly
important in high risk patients and those who received cord
blood graft or are under steroid treatment (Lindemans et al.,
2010). High AdV levels in stool have also been associated
with gastrointestinal AdV disease (Feghoul et al., 2015) – an
observation that underpins a current clinical trial addressing
the usefulness of a preemptive treatment based on stool AdV
detection2. So far, no recommendation has been made for AdV
detection in upper airways. Specific treatment of AdV pneumonia
should be given as early as possible after diagnosis (Neofytos et al.,
2007; Lindemans et al., 2010).
Several studies have reported successful Cidofovir treatment
of AdV infections in immunocompromised hosts after HCT,
combined with withdrawal of immunosuppression (e.g., at
5 mg/kg once every week for 2 weeks, followed by a maintenance
dose of 5 mg/kg once every fortnight, or three times weekly
at 1 mg/kg) (Lindemans et al., 2010; Wy Ip and Qasim, 2013).
Cidofovir inhibits incorporation of deoxycytidine triphosphate
2https://clinicaltrials.gov/ct2/show/NCT03481244
into viral DNA by the viral DNA polymerase, leading to viral
DNA chain termination. Probenecid co-prescription is useful
to prevent or diminish cidofovir nephrotoxicity due to its
accumulation in renal tubules. Cidofovir is the current standard
of care treatment for AdV infections and diseases. However,
cidofovir does not clear the virus in the absence of T cell immune
reconstitution (Hiwarkar et al., 2017).
Another novel compound is CMX001 (hexadecyloxypropyl
cidofovir, brincidofovir, Chimerix), an orally bioavailable lipid
conjugate of cidofovir with good oral bioavailability which
achieves higher intracellular levels of active drug compared
with cidofovir. Brincidofovir lacks nephrotoxicity making it an
attractive alternative. In phase I and phase II trials as well as in
retrospective studies, brincidofovir has been shown to be highly
efficacious in controlling and clearing adenoviraemia (Grimley
et al., 2017; Hiwarkar et al., 2017; Ramsay et al., 2017; Averbuch
et al., 2018). Gastrointestinal toxicity is the major side effect
observed and might be associated with epithelial apoptosis and
crypt injury, as might be observed with GvHD (Detweiler et al.,
2018).
Further, a small compound inhibitor named HBX has been
reported to be effective against AdV infections. A cellular
component important for AdV replication is ubiquitin-specific
protease 7 (USP-7), a deubiquitinating enzyme of the ubiquitin
proteasome pathway. USP-7 interacts with E1B-55K, a regulator
of AdV replication. Since USP-7 promotes AdV replication,
it represents a potential drug target because blocking its
activity could aid in the treatment of AdV infections (Ching
et al., 2013). HBX and a derivative were generated that
were able to block AdV (C5 type) replication. With the
exception of AdV types A12 and A31, HBX effectively
blocked in vitro replication of all AdV tested, making
it a promising new antiviral candidate (Kosulin et al.,
2018b).
For AdV, there is no proven role for ganciclovir, foscarnet
or immunoglobulin therapy in immunocompromised patients.
Importantly, donor lymphocyte infusions and more recently
specific anti AdV cytototoxic T cells should be considered
in case of AdV disease after HCT (see below). There is
anecdotal evidence of successful treatment of AdV with
ribavirin (Schleuning et al., 2004) but most studies have not
been supportive; (Lankester et al., 2004) and conclude that
cidofovir combined with immunotherapy is more efficient and
should be preferred as the first treatment option. Of note,
Ribavirin is active in vitro on species C isolates (Morfin et al.,
2005).
HBoV, HCoV, and RhV
There is currently no recommendation of specific antiviral
therapy due to the lack of effective agents against these viruses
and the lack of clinical trials (Hirsch et al., 2013). Several
agents against RhV have been described in the context of
immunosuppression: Oral or intranasal pleconaril, a capsid
binder, was effective in 2 randomized trials to mildly reduce the
duration and severity of colds in immunocompetent adults but
its development was halted after FDA rejection partly due to
concerns regarding virus resistance (Senior, 2002). Vapendavir is
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another capsid binder under development3 for the treatment of
RhV infections of asthmatic adults (Waghmare et al., 2016).
Influenza Virus
To avoid transmission of IFV, vaccination of family members,
household contacts and HCT recipients is recommended.
However, HCT recipients might not mount an adequate immune
response if vaccination takes place during immunosuppression.
Available antivirals for IFV infections include the M2 ion channel
inhibitors such as amantadine that exclusively act on IFV-
A. However, neuraminidase inhibitors (NAI) are preferred for
prophylaxis and treatment of IFV infections since resistance to
M2 inhibitors is frequent (Englund et al., 1998; Fiore et al.,
2011; von Lilienfeld-Toal et al., 2016). Post exposure prophylaxis
with oral oseltamivir, 75 mg bid for 10 days for adults and
children whose weight is above 40 kg, is the current treatment
of choice. Oral oseltamivir, inhaled zanamivir and IV peramivir
are NAIs that were shown to be effective in HCT recipients
(Vu et al., 2007; Tomblyn et al., 2009; Casper et al., 2010;
Choi et al., 2011; Engelhard et al., 2013). Treatment within
48 h after the occurrence of symptoms will result in better
outcome (Ljungman et al., 2001; Nichols et al., 2004b; Tomblyn
et al., 2009; Choi et al., 2011; Engelhard et al., 2013); Although
treatment should be initiated as early as possible, protracted and
also prolonged treatment have been shown to have favorable
effects. The duration of therapy should extend the treatment
period recommended for immunocompetent hosts to circumvent
reoccurrence and might last for 10 days in HCT recipients.
Also, longer therapy in case of unsuccessful clearance might be
necessary (Engelhard et al., 2013).
The most commonly described mutation resulting in
oseltamivir and peramivir resistance is conferred by the H275Y
mutation in influenza A H1N1 that can be treated with inhaled
zanamivir (Memoli et al., 2010; Engelhard et al., 2013). In
Europe during the 2007–2008 winter season, high resistance
rates up to 68% of IFV-A (H1N1) to oseltamivir have been
reported (Meijer et al., 2009). New agents with potential
efficacy against oseltamivir-resistant viruses are being tested like
inhaled laninamivir which is available in Japan, JNJ-63623872,
a non-nucleoside inhibitor of the RNA polymerase protein
PB2, Nitazoxanide, an antiparasitic agent with activity against
IFV, and antibodies (MEDI8852, VIS410) (Shahani et al.,
2017).
Parainfluenza Virus
In a retrospective analysis of 200 patients including 120
HCT recipients, one-third of patients with PIV infection had
lower respiratory tract disease and independent risk factors of
progression were neutropenia, APACHE II score ≥ 15, and
respiratory co-infections within a month of PIV infection. In this
study, treatment with aerosolized ribavirin and/or IVIG did not
prevent progression to pneumonia and did not affect duration
of illness or survival (Chemaly et al., 2012). A meta-analysis
performed in 2016 reinforced this evidence of inefficiency of
ribavirin for PIV: indeed, PI-LRI progression was not significantly
3https://clinicaltrials.gov/ct2/show/NCT02367313
different in HCT recipients who were treated with ribavirin at
URI stage, and PIV-associated mortality rate was slightly higher
in patients treated with ribavirin-based therapy at LRI stage than
in those who were not treated (Shah et al., 2016a). A recombinant
sialidase fusion protein inhibitor named DAS181 has been used
to treat severe PIV infections after HCT (Waghmare et al.,
2015; Dhakal et al., 2016; Salvatore et al., 2016). DAS181
cleaves the Neu5Ac α(2,3)-Gal and Neu5Ac α(2,6)-Gal sialic
acid linkages on the surface of respiratory cells that are used
by IFV and PIV for attachment and entry, thereby inhibiting
the latter. The largest cohort included 16 patients after HCT,
14 of who received DAS181 for PIV-associated pneumonia but
unfortunately lacked a control group (Salvatore et al., 2016).
Thirteen out of 16 patients responded to treatment, and the
three patients who did not respond had a viral, bacterial, or
fungal co-infection, respectively. The drug was well tolerated. PIV
loads were recorded in 7 of 16 patients using nasopharyngeal
swabs. A > 1 log decrease in PIV load was seen in 5 of 7
patients accompanied by a partial or complete clinical response.
High-dose IVIG had no effect on mortality after PIV LRI in a
retrospective analysis of 544 patients with PIV infection after
HCT (Seo et al., 2014a). Therefore, no specific treatment for PIV
infection is currently strongly recommended. However, current
ECIL-4 guidelines suggest treatment with aerosolized ribavirin
or off-label use with systemic ribavirin. For infections other than
PIV and RSV, ribavirin use is not recommended (Hirsch et al.,
2013).
Human Metapneumovirus
In a study among 105 patients with URI from the Fred
Hutchinson Cancer Center (Seo et al., 2016), the probability of
progression to LRI within 40 days was 16%, and approximately
75% of the patients with URI who progressed to LRI did so within
2 weeks after URI. Even if several small reports support the use
of ribavirin with or without IVIG for HMPV infection, a larger
study showed no protective effect of ribavirin to reduce HMPV
progression and mortality (Renaud et al., 2013). To date, antiviral
therapy is not recommended to cure or to prevent infection
progression even in patients at higher risk of HMPV progression.
No licensed therapeutics or vaccines exist (Wen and Williams,
2015). Therefore, treatment for HMPV remains so far non-
specific and mainly supportive. MAb 338, a monoclonal antibody
against a fusion protein of HMPV, demonstrated interesting
results in hamster and mice models, and further investigation in
clinical trials is warranted (Ulbrandt et al., 2006; Hamelin et al.,
2010).
Respiratory Syncytial Virus
In 2013, international guidelines recommended aerosolized or
systemic (oral or IV) ribavirin with IVIG in patients with RSV
URI undergoing allogeneic HCT, allogeneic HCT recipients with
risk factors for progression to LRI, and allogeneic HCT patients
with LRI (Hirsch et al., 2013). However, the additional benefit
of IVIG remains controversial. In a retrospective study that
reviewed RSV URI or LRI infections in 280 HCT recipients,
a combined IVIG and ribavirin treatment was beneficial (Shah
et al., 2013). Further, given significant exponential cost increases
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in aerosolized ribavirin between 2013 and 2015 and lack of
evidence that aerosolized ribavirin is more efficient, early oral
ribavirin treatment is currently more frequently considered
(Waghmare et al., 2016) and is well tolerated (e.g., 15 mg/kg/day
in three divided doses for 10 days) (Gorcea et al., 2017). A clinical
trial comparing RSV treatment with oral versus inhaled ribavirin
is ongoing4. However, in France, aerosolized ribavirin is currently
not available.
Lymphopenia is a specific risk factor that has been associated
with progression to LRTI in several studies. Other risk factors
such as total body irradiation, smoking history, stem cell source
other than peripheral blood stem cells and oxygen requirement
might be considered (Seo et al., 2013; Waghmare et al., 2013).
A lower virulence of RSV-B compared to RSV-A has been
reported (Kelly et al., 2016). As stated above, the ISI might be
helpful to identify patients who would benefit from antiviral
therapy (Shah et al., 2016a).
Data from studies with the RSV-specific monoclonal antibody
palivizumab have shown controversial efficacy, apart from the
fact that it is very costly in adults. In larger studies of HCT
recipients with RSV LRI, adjunctive palivizumab did not lead
to outcome improvement (Seo et al., 2013; Waghmare et al.,
2013). Therefore, RSV-specific monoclonal antibody is not
recommended as a treatment option and might be only discussed
4https://clinicaltrials.gov/ct2/show/NCT01502072
for very young (age < 2 years) allogeneic HCT recipients with
LRI or at high risk for progression to RSV LRI (e.g., palivizumab
15 mg/kg body weight) (Hirsch et al., 2013).
Moreover, several agents are under development against
RSV infections (Shahani et al., 2017). Firstly, there are fusion
inhibitors like GS-5806 which reduced the viral load and
the severity of clinical disease in a study of healthy adults
(DeVincenzo et al., 2014), MDT-6375 and ALX-0171. Secondly,
agents targeting the RSV polymerase exist: AL-8176 which had
an interesting antiviral activity compared to placebo in 62
healthy adults inoculated with RSV (DeVincenzo et al., 2015)
and favipiravir which is currently being tested in phase III
clinical trials in the United States, Europe, and Latin America.
Thirdly, substances targeting the viral nucleocapsid protein
have been investigated. A small interfering RNA called ALN
RSV01 inhibiting the synthesis of the RSV nucleocapsid protein
has demonstrated a benefit in phase I to IIb clinical trials
by decreasing the infection rate, reducing symptoms and the
incidence of bronchiolitis obliterans. Another drug, RSV-604,
targets the N terminal portion of the nucleocapsid protein. It was
tested on HCT recipients, however, no data have been published
(Simões et al., 2015). Finally, polyclonal high-titer anti RSV
antibodies might be an option (RI-001)6.
5https://clinicaltrials.gov/ct2/show/NCT01556607
6https://clinicaltrials.gov/ct2/show/NCT00632463
TABLE 1 | Treatment algorithm of respiratory viral infections after HCT.
(1) Steroid dose withdrawal (if applicable) below 1 mg/kg/day (except for IFV)
↓
(2) In case of LRI or high risk factors: start specific treatment
↓












Oral oseltamivir 75 mg bid
(30 mg bid 10–15 kg, 45 mg
bid 16–23 kg,. 60mg bid
24-40 kg) for 10 days










NAI: inhaled zanamivir IV
peramivir Zanamivir (if

















HBX Inhaled laninamivir Nitazoxanide
MEDI8852 VIS410
↓
(3) Virus spread prophylaxis: hand hygiene, surgical mask, vaccination of family, prolonged isolation
AdV, adenovirus; HMPV, human metapneumovirus; RhV, rhinovirus; IFV, influenza virus ; IVIG, intravenous polyvalent immunoglobulins ; LRI, lower respiratory tract infection;
NAI, neuraminidase inhibitor; PIV, parainfluenza virus; RSV, respiratory syncytial virus.
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Current strategies recommended for the treatment of
respiratory viral disease after HCT, and molecules that are under
investigation, are summarized in Table 1.
Immunotherapy After HCT
Before the era of specific antiviral manufactured T
cells, donor lymphocyte infusions (DLI) were used and
recommended in case of disseminated AdV infections
after HCT (Bordigoni et al., 2001; Taniguchi et al., 2012).
The high incidence of GvHD after DLIs limits its use in
patients with previous history of GvHD. Anecdotal use of
DLI has been reported for threatening RSV LRI (Kishi et al.,
2000).
There are currently three strategies to manufacture viral
specific T cells (VST) for clinical use: The first one is direct
selection of antiviral T cells, either by multimers specific
for a virus-derived peptide in the setting of class I HLA
molecule, or by column selection of IFN-γ expressing T cells
(with immunomagnetic beads) after viral antigen stimulation
(Feuchtinger et al., 2006; Peggs et al., 2011; Icheva et al.,
2013). The second one is ex vivo expansion of T cells co-
cultured with antigen presenting cells pulsed, infected or
transfected with viral peptide/protein/viral lysate or plasmid
(Peggs et al., 2003; Gerdemann et al., 2012, 2013). The third
one is genetic modification of T cells which incorporate high
affinity VSTs receptor or chimeric antigen receptor genes
(Schub et al., 2009; Cruz et al., 2013; Bollard and Heslop,
2016).
So far, in the setting of community acquired viral respiratory
infections, adoptive immune therapy has been developed and
investigated in clinical trials only for AdV infections. This
strategy is promising as it has been reported to offer a way
to cure severe adenoviral infections in case of resistance to
antiviral drugs. Adenoviral clearance has been obtained after
infusions of AdV-VST generated by interferon [IFN-γ-based
immunomagnetic isolation (and further in vivo expansion) from
initial donor or third party donor] in 10 of 11 hematopoietic
stem cells transplanted patients in a French phase I/II trial
(Qian et al., 2017). Similar results have been published earlier
(Feucht et al., 2015) from 30 patients who received AdV-VST
for AdV disease or viremia. 14 of 23 evaluable patients had
in vivo expansion of Th1-VST (median time 24 days); and
21 patients responded to VST infusions and AdV clearance
occurred in 14. Of note, AdV-VST infusions were not associated
with acute toxicities or significant onset of GvHD. The
main disadvantage of this technique is that high doses of
immunosuppressive drugs and especially steroids should be
avoided before infusions as this drug hampers in vivo expansion
of specific T cells.
Currently, multiviral (including AdV) T cell manufacturing
and banking from a third-party donor is a promising strategy
as it might offer an immediate way to prevent AdV infections
after HCT or to cure 71% of AdV infected patients after
HCT (Tzannou et al., 2017). Ex vivo expanded cytotoxic
T cells against PIV-3 antigens should be further tested in
clinical trials (McLaughlin et al., 2016; Aguayo-Hiraldo et al.,
2017).
Outcomes and Later Monitoring
Overall Mortality and Risk Factors
The outcome in patients who experience progression to LRI is
worse compared to patients with URI regardless of the virus
involved (Chemaly et al., 2014). In a French cohort of 131 adult
patients infected with viral respiratory infections, 16 (12%) died
within 3 months. Among these, eight patients (6%) died of
viral pneumonia along with bacterial and/or fungal pneumonia.
Interestingly, the virus group and the time from HCT had no
impact on mortality. Two factors were independently associated
with increased overall mortality: steroid dose over 1 mg/kg body
weight and a lymphocyte count lower than 0.5 g/L (Wolfromm
et al., 2014). The fact that LRI associated death risk does not
depend on the virus type is supported by Seo et al. (2017)
who reported an overall mortality probability at day 90 as
high as 41% in patients after HCT who developed RhV LRI,
a rate that was comparable to RSV, PIV and IFV LRI in an
adjusted model. Among children, in a cohort of 58 patients,
3 (5%) died of respiratory failure (Choi et al., 2013). LRI in
the absence of URI and adenoviral infection has been described
to be associated with a poorer outcome in another cohort of
166 patients with specific overall mortality of 7% (Lo et al.,
2013).
Pulmonary Outcomes After Viral Infections
Bronchiolitis obliterans syndrome and obstructive airflow decline
have been associated with PIV and RSV infections within
the first 3 months after allogeneic HCT which persisted
at 1 year after transplant (Versluys et al., 2010). Further,
the occurrence of a LRI within 100 days post-transplant
was an independent predictive factor for late onset non-
infectious pulmonary complications diagnosed in the first
36 months after transplantation in an observational prospective
cohort study on 198 patients (Bergeron et al., 2018). Therefore,
functional pulmonary explorations and long-term surveillance
are warranted after community acquired viral infections which
occurred early after HCT. To better understand risk factors of
pulmonary complications in children after HCT, a multicentric
French trial is ongoing7. Early treatment with β2 mimetics and
inhaled steroids might be useful and should be proposed in case of
persistent obstructive syndrome after respiratory viral infections
resolution in HCT recipients.
CONCLUDING DISCUSSION
This review has limitations because we present results from
small case series that have restricted meaningfulness. Further, it
includes recommendations that were in part made before the era
of T cell repleted haploidentical transplantations. This is an area
of intense research and these new developments might impact the
epidemiology and outcomes of viral infections after HCT.
Respiratory virus infections continue to cause disease both
in the pre-transplant as well as in the post-transplant period
and should be taken very seriously, especially in children who
7https://clinicaltrials.gov/ct2/show/NCT02032381
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tend to shed virus for longer periods. This long shedding time
has implications for infection control. Therefore, both personnel
and patients and their families should be properly instructed
in hand hygiene. In case of pre-transplant infections, HCT
should be deferred but the underlying disease, the conditioning
regimen and donor availability need to be considered. In pediatric
patients who also tend to acquire viruses more frequently, we
favor transplant delay in elected cases, even in asymptomatic
patients.
Without doubt, disease progression from URI to LRI
influences the outcome in HCT recipients. There are a number of
risk factors shared by respiratory viruses that are associated with
LRI occurrence; lymphopenia appears to be a specific risk factor
in this case. Other risk factors shared with increased mortality
are steroid use at the time of LRI diagnosis, oxygen requirement
at the time of BAL, and severity of disease based on APACHE II
score. In addition, myeloablative conditioning, GvHD, bacterial
as well as fungal pulmonary co-infections (especially with IFV
and PIV infections) seem to worsen the outcome.
Is there a possibility to reduce the risk of progression from
URI to LRI? There might be a chance if co-infections can be
reduced or diagnosed and treated promptly. These co-infections
could be more easily avoided if they were nosocomially acquired
by transfer from personnel or visitors. Therefore, people who
have access to the patient should be aware of this problem. Also,
shortening of the lymphopenic interval could reduce disease
progression. This might be achieved with a stricter withdrawal
of immunosuppressive drugs, e.g., steroids, or a milder form of
conditioning.
Early and specific diagnostics are of the essence. It would
be best to obtain diagnostic samples straight from the area of
infection, i.e., from BAL material and not a nasal swab in case of
a LRI, however, this might be sometimes impractical and not be
tolerated by the patient. Unless a specific viral agent is suspected
and a single or duplex PCR are ordered, e.g., during an outbreak,
novel multiplex assays should be employed that also identify
a bacterial co-infection. What is more, novel multiplex assays
that are able to quantify viral loads clearly have the potential
to help identify which patients are at increased risk and who
might need treatment urgently – particularly since supporting
measures like radiological imaging techniques often do not point
to a specific pathogen and provide non-specific results with
regard to identification of the pathogen responsible. However,
while chest x-rays discover inflammatory processes with delay,
CT findings might help to differentiate between pathogens. All
these diagnostic steps should be carried out after full evaluation of
the circumstances and in an orderly fashion. The ISI and the RSI
(Tables 2, 3) might be helpful to identify patients at risk but await
validation in clinical trials. Eventually, only few antivirals are
available and licensed to treat respiratory virus infections. Several
drugs have been tested in HCT recipients and promising results
have been published. Novel antiviral compounds are urgently
required that might be used in combination with antiviral
lymphocytes as currently being developed for CMV, EBV, AdV,
or BK antivirus CTLs in US (NCT01945814, NCT01570283) and
European international trials (the TRACE trial). The production
of these cells should be confined to specialized laboratories, either
TABLE 2 | Immunodeficiency scoring index (ISI) for RSV.
Criteria Weighing criteria Assigned weights (score)
ANC < 500/µL >2.5 3
ALC < 200/µL >2.5 3














Low risk: 0–2 score, moderate risk 3–6 score, high risk 7–12 score
ANC, absolute neutrophil count; ALC, absolute lymphocyte count; GVHD, graft-
versus-host disease; Modified after Shah et al. (2014).
TABLE 3 | Scoring algorithm of the Radiologic Severity Index (RSI).
Lung zones (3 left lobe, 3 right lobe; 6 total) are evaluated by chest x-ray
and CT scan; for each lobe there are three zones: (a) upper (above












1 Normal lung 0 0% (normal)
2 Ground-glass opacities 1 1–24%
3 Consolidation 2 25–49%
3 50–74%
4 75–100%
To calculate the RSI score, the predominant pattern for each lung zone is multiplied
with the extent of the volumetric radiologic involvement, e.g., if ground-glass
opacities are detected in all six lung zones with all having a volumetric score of
3, the RSI score would be 36 (2 × 3 × 6). The maximum score is 72. Modified after
Sheshadri et al. (2018).
university-based or commercial, however, they should be easily
accessible. The expansion of this approach to target respiratory
viruses might be similarly useful to halt disease progression from
URI to LRI.
Finally, the application of CAR T cells to combat respiratory
viral infections might be an option in the future, especially
in combination with tumor targeting CAR T cells. However,
pulmonary toxicity should be considered due to cross-reactivity
of CAR T cells with non-targeted proteins, and also ARDS that
often occurs in severe LRI might be worsened by cytokine release
syndrome. While viral pneumonia still remains a concern in HCT
patients, new drug developments, along with sophisticated T cell
approaches, should diminish complications caused by respiratory
viruses.
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